068760 — Celltrion Pharm Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩4tn
- KR₩4tn
- KR₩389bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 13,332 | 29,748 | 88,161 | 44,093 | 32,211 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 139,466 | 142,016 | 174,008 | 187,608 | 222,499 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 188,855 | 230,954 | 331,140 | 311,918 | 364,831 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 216,577 | 248,256 | 241,925 | 228,243 | 220,762 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 470,980 | 548,075 | 637,884 | 599,725 | 641,644 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 149,139 | 184,927 | 259,914 | 211,998 | 249,346 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 190,949 | 247,514 | 305,916 | 242,938 | 264,978 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 280,031 | 300,561 | 331,969 | 356,787 | 376,666 |
Total Liabilities & Shareholders' Equity | 470,980 | 548,075 | 637,884 | 599,725 | 641,644 |
Total Common Shares Outstanding |